Showing 4741-4750 of 8832 results for "".
- Patricia Treadwell, MD Assumes Presidency of Society for Pediatric Dermatologyhttps://practicaldermatology.com/news/patricia-treadwell-md-assumes-presidency-of-society-fir-pediatric-dermatology/2460888/Patricia Treadwell, MD is new President of the Society for Pediatric Dermatology (SPD). She assumed the role and the society and seated its new 2021-2022 Executive Committee members during the 46th Annual Conference last month. Dr. Treadwell is jo
- FDA Accepts Dermavant's NDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-dermavants-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis/2460886/The FDA has accepted Dermavant Sciences' New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and
- Vivacare Calls on Derms to Share Knowledge During Psoriasis Awareness Monthhttps://practicaldermatology.com/news/vivacare-calls-on-terms-to-share-knowledge-during-national-psoriasis-month/2460885/Dermatologists from around the country have contributed tips to Vivacare’s education resources and Physician Directory, and the company is inviting others to join in. In honor of Psoriasis Awareness Month, Vivacare is requesting dermatologists share insights regarding psoriasis and its trea
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- Strand Therapeutics Scores Two Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancerhttps://practicaldermatology.com/news/strand-therapeutics-scores-two-grants-to-advance-programmable-long-lasting-mrna-therapeutics-for-melanoma-and-breast-cancer/2460881/Strand Therapeutics was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total fund
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officerhttps://practicaldermatology.com/news/industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/2460879/Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical c
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- Hot Off the Press: Dr. Brooke Jackson’s New Book “Skin Care for Runners” Now Availablehttps://practicaldermatology.com/news/hot-off-the-press-dr-brooke-jacksons-new-book-skin-care-for-runners-now-available/2460875/Durham, NC-based dermatologist Dr. Brooke Jackson’s new book, “Skin Care for Runners”, is now available. The book is the definitive guide to healthy skin and nails for runners—and all athletes. In it, Dr. Jackson, also marathoner, offers tips and